by Portfolio Grader | October 9, 2013 11:15 am
Seven Biotechnology stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an “A” (“strong buy”) or “B” overall (“buy”).
MiMedx Group, Inc. (NASDAQ:MDXG) ups its rating to a B (“buy”) this week after earning a C (“hold”) in the week before. In Portfolio Grader’s specific subcategory of Sales Growth, MDXG also gets an A. MiMedx Group together with its subsidiaries, operates as an integrated developer, manufacturer, and marketer of patent protected regenerative biomaterial products and allografts processed from human amniotic membranes. Shares of MDXG have increased 22.1% over the past month, better than the 1.3% decrease the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of MDXG stock.
Mirati Therapeutics Inc. (NASDAQ:MRTX) shows solid improvement this week. Mirati Therapeutics engages in the development of therapeutics for the cancer treatment. The company’s rating rises from a C to a B. For more information, get Portfolio Grader’s complete analysis of MRTX stock.
This is a strong week for ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA). The company’s rating climbs to B from the previous week’s C. ARIAD Pharmaceuticals is an oncology company that focuses on the discovery, development, and commercialization of medicines for cancer patients. Shares of the stock have been trading at an exceptionally rapid pace, up twofold from the week prior. For more information, get Portfolio Grader’s complete analysis of ARIA stock.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) improves from a C to a B rating this week. Neurocrine Biosciences is focused on the discovery and development of therapeutics for neuropsychiatric, neuroinflammatory, and neurodegenerative diseases and disorders. The stock price has been on the rise for the past three days, reaching $10.76. For more information, get Portfolio Grader’s complete analysis of NBIX stock.
Array BioPharma’s (NASDAQ:ARRY) ratings are looking better this week, moving up to a B from last week’s C. Array BioPharma is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory and metabolic diseases. After five consecutive days of gains, the stock price has reached $5.79. For more information, get Portfolio Grader’s complete analysis of ARRY stock.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) is making headway this week, with the company’s rating improving to an A (“strong buy”) from a B (“buy”) last week. Celldex Therapeutics is engaged in the discovery, development and commercialization of products that harness the human immune system to prevent and treat disease. The stock price has pushed upwards for the past six days, reaching $28.95. Shares of the stock have been changing hands at an unusually rapid pace, twice the rate of the week prior. For more information, get Portfolio Grader’s complete analysis of CLDX stock.
Insmed Incorporated (NASDAQ:INSM) boosts its rating from a C to a B this week. Insmed develops and commercializes drugs that treat metabolic diseases, endocrine disorders and oncology. The stock finished at $13.87 per share, after five days of consecutive gains. For more information, get Portfolio Grader’s complete analysis of INSM stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
Source URL: http://investorplace.com/2013/10/7-biotechnology-stocks-to-buy-now-mdxg-mrtx-aria/
Short URL: http://invstplc.com/1nukZGY
Copyright ©2017 InvestorPlace Media, LLC. All rights reserved. 700 Indian Springs Drive, Lancaster, PA 17601.